Search

Your search keyword '"Caruntu, Florin A."' showing total 128 results
Start Over Author "Caruntu, Florin A."
128 results on '"Caruntu, Florin A."'

1. Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022

Author

Yurdaydin, Cihan, Roulot, Dominique, Zoulim, Fabien, Caruntu, Florin Alexandru, Wedemeyer, Heiner, Kefalakes, Helenie, Lucifora, Julie, Agarwal, Kosh, Castera, Laurent, Buti, Maria, Rizzetto, Mario, Cornberg, Markus, Dandri, Maura, Brunetto, Maurizia, Reau, Nancy, Gish, Robert, Hamid, Saeed, Aleman, Soo, Urban, Stephan, Asselah, Tarik, Berg, Thomas, de Lédinghen, Victor, Lampertico, Pietro, Degasperi, Elisabetta, and Sandmann, Lisa

Published
2023
Full Text
View/download PDF

2. Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety

Author

Chan, Henry L.Y., Buti, Maria, Lim, Young Suk, Agarwal, Kosh, Marcellin, Patrick, Brunetto, Maurizia, Chuang, Wan Long, Janssen, Harry L.A., Fung, Scott, Izumi, Namiki, Abdurakhmanov, Dzhamal, Jabłkowski, Maciej, Celen, Mustafa K., Ma, Xiaoli, Caruntu, Florin, Flaherty, John F., Abramov, Frida, Wang, Hongyuan, Camus, Gregory, Osinusi, Anu, Pan, Calvin Q., Shalimar, Seto, Wai Kay, Gane, Edward, Chan, Henry L.Y., Buti, Maria, Lim, Young Suk, Agarwal, Kosh, Marcellin, Patrick, Brunetto, Maurizia, Chuang, Wan Long, Janssen, Harry L.A., Fung, Scott, Izumi, Namiki, Abdurakhmanov, Dzhamal, Jabłkowski, Maciej, Celen, Mustafa K., Ma, Xiaoli, Caruntu, Florin, Flaherty, John F., Abramov, Frida, Wang, Hongyuan, Camus, Gregory, Osinusi, Anu, Pan, Calvin Q., Shalimar, Seto, Wai Kay, and Gane, Edward

Abstract

INTRODUCTION: The results from 2 phase 3 studies, through 2 years, in chronic hepatitis B infection showed tenofovir alafenamide (TAF) had similar efficacy to tenofovir disoproxil fumarate (TDF) with superior renal and bone safety. We report updated results through 5 years. METHODS: Patients with HBeAg-negative or HBeAg-positive chronic hepatitis B infection with or without compensated cirrhosis were randomized (2:1) to TAF 25 mg or TDF 300 mg once daily in double-blind (DB) fashion for up to 3 years, followed by open-label (OL) TAF up to 8 years. Efficacy (antiviral, biochemical, and serologic), resistance (deep sequencing of polymerase/reverse transcriptase and phenotyping), and safety, including renal and bone parameters, were evaluated by pooled analyses. RESULTS: Of 1,298 randomized and treated patients, 866 receiving TAF (DB and OL) and 432 receiving TDF with rollover to OL TAF at year 2 (n = 180; TDF→TAF3y) or year 3 (n = 202; TDF→TAF2y) were included. Fifty (4%) TDF patients who discontinued during DB were excluded. At year 5, 85%, 83%, and 90% achieved HBV DNA <29 IU/mL (missing 5 failure) in the TAF, TDF→TAF3y, and TDF→TAF2y groups, respectively; no patient developed TAF or TDF resistance. Median estimated glomerular filtration rate (by using Cockcroft-Gault) declined <2.5 mL/min, and mean declines of <1% in hip and spine bone mineral density were seen at year 5 in the TAF group; patients in the TDF→TAF groups had improvements in these parameters at year 5 after switching to OL TAF. DISCUSSION: Long-term TAF treatment resulted in high rates of viral suppression, no resistance, and favorable renal and bone safety.

Published
2024

3. Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection

Author

Zuckerman, Eli, Gutierrez, Julio A., Dylla, Douglas E., de Ledinghen, Victor, Muir, Andrew J., Gschwantler, Michael, Puoti, Massimo, Caruntu, Florin, Slim, Jihad, Nevens, Frederik, Sigal, Samuel, Cohen, Stanley, Fredrick, Linda M., Pires dos Santos, Ana Gabriela, Rodrigues, Lino, Jr., and Dillon, John F.

Published
2020
Full Text
View/download PDF

4. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial

Author

Wedemeyer, Heiner, Yurdaydin, Cihan, Hardtke, Svenja, Caruntu, Florin Alexandru, Curescu, Manuela G, Yalcin, Kendal, Akarca, Ulus S, Gürel, Selim, Zeuzem, Stefan, Erhardt, Andreas, Lüth, Stefan, Papatheodoridis, George V, Keskin, Onur, Port, Kerstin, Radu, Monica, Celen, Mustafa K, Idilman, Ramazan, Weber, Kristina, Stift, Judith, Wittkop, Ulrike, Heidrich, Benjamin, Mederacke, Ingmar, von der Leyen, Heiko, Dienes, Hans Peter, Cornberg, Markus, Koch, Armin, and Manns, Michael P

Published
2019
Full Text
View/download PDF

5. Five‐year follow‐up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

Author

Anastasiou, Olympia E., primary, Caruntu, Florin A., additional, Curescu, Manuela G., additional, Yalcin, Kendal, additional, Akarca, Ulus S., additional, Gürel, Selim, additional, Zeuzem, Stefan, additional, Erhardt, Andreas, additional, Lüth, Stefan, additional, Papatheodoridis, George V., additional, Keskin, Onur, additional, Port, Kerstin, additional, Radu, Monica, additional, Celen, Mustafa K., additional, Idilman, Ramazan, additional, Heidrich, Benjamin, additional, Mederacke, Ingmar, additional, von der Leyen, Heiko, additional, Kahlhöfer, Julia, additional, von Karpowitz, Maria, additional, Hardtke, Svenja, additional, Cornberg, Markus, additional, Yurdaydin, Cihan, additional, and Wedemeyer, Heiner, additional

Published
2023
Full Text
View/download PDF

6. Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022

Author

Lampertico, Pietro, primary, Degasperi, Elisabetta, additional, Sandmann, Lisa, additional, Wedemeyer, Heiner, additional, Yurdaydin, Cihan, additional, Roulot, Dominique, additional, Zoulim, Fabien, additional, Caruntu, Florin Alexandru, additional, Kefalakes, Helenie, additional, Lucifora, Julie, additional, Agarwal, Kosh, additional, Castera, Laurent, additional, Buti, Maria, additional, Rizzetto, Mario, additional, Cornberg, Markus, additional, Dandri, Maura, additional, Brunetto, Maurizia, additional, Reau, Nancy, additional, Gish, Robert, additional, Hamid, Saeed, additional, Aleman, Soo, additional, Urban, Stephan, additional, Asselah, Tarik, additional, Berg, Thomas, additional, and de Lédinghen, Victor, additional

Published
2023
Full Text
View/download PDF

7. Five‐year follow‐up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.

Author

Anastasiou, Olympia E., Caruntu, Florin A., Curescu, Manuela G., Yalcin, Kendal, Akarca, Ulus S., Gürel, Selim, Zeuzem, Stefan, Erhardt, Andreas, Lüth, Stefan, Papatheodoridis, George V., Keskin, Onur, Port, Kerstin, Radu, Monica, Celen, Mustafa K., Idilman, Ramazan, Heidrich, Benjamin, Mederacke, Ingmar, von der Leyen, Heiko, Kahlhöfer, Julia, and von Karpowitz, Maria

Subjects
*HEPATITIS D, *HEPATITIS D virus, *TENOFOVIR, *CIRRHOSIS of the liver, *HEPATOCELLULAR carcinoma
Abstract

Background & Aims: Until recently, pegylated interferon‐alfa‐2a (PEG‐IFNa) therapy was the only treatment option for patients infected with hepatitis D virus (HDV). Treatment with PEG‐IFNa with or without tenofovir disoproxil fumarate (TDF) for 96 weeks resulted in HDV RNA suppression in 44% of patients at the end of therapy but did not prevent short‐term relapses within 24 weeks. The virological and clinical long‐term effects after prolonged PEG‐IFNa‐based treatment of hepatitis D are unknown. Methods: In the HIDIT‐II study patients (including 40% with liver cirrhosis) received 180 μg PEG‐IFNa weekly plus 300 mg TDF once daily (n = 59) or 180 μg PEG‐IFNa weekly plus placebo (n = 61) for 96 weeks. Patients were followed until week 356 (5 years after end of therapy). Results: Until the end of follow‐up, 16 (13%) patients developed liver‐related complications (PEG‐IFNa + TDF, n = 5 vs PEG‐IFNa + placebo, n = 11; p =.179). Achieving HDV suppression at week 96 was associated with decreased long‐term risk for the development of hepatocellular carcinoma (p =.04) and hepatic decompensation (p =.009). Including complications irrespective of PEG‐IFNa retreatment status, the number of patients developing serious complications was similar with (3/18) and without retreatment with PEG‐IFNa (16/102, p >.999) but was associated with a higher chance of HDV‐RNA suppression (p =.024, odds ratio 3.9 [1.3–12]). Conclusions: Liver‐related clinical events were infrequent and occurred less frequently in patients with virological responses to PEG‐IFNa treatment. PEG‐IFNa treatment should be recommended to HDV‐infected patients until alternative therapies become available. Retreatment with PEG‐IFNa should be considered for patients with inadequate response to the first course of treatment. Clinical Trial registration: NCT00932971. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis

Author

Ahn, Sang Hoon, Marcellin, Patrick, Ma, Xiaoli, Caruntu, Florin A., Tak, Won Young, Elkhashab, Magdy, Chuang, Wan-Long, Tabak, Fehmi, Mehta, Rajiv, Petersen, Jörg, Guyer, William, Jump, Belinda, Chan, Alain, Subramanian, Mani, Crans, Gerald, Fung, Scott, Buti, Maria, Gaeta, Giovanni B., Hui, Aric J., Papatheodoridis, George, Flisiak, Robert, and Chan, Henry L. Y.

Published
2018
Full Text
View/download PDF

9. Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

Author

Anastasiou, Olympia Aevdoxia, primary, Caruntu, Florin Alexandru, additional, Curescu, Manuela Gabriela, additional, Yalcin, Kendal, additional, Akarca, Ulus S, additional, Gurel, Selim, additional, Zeuzem, Stefan, additional, Erhardt, Andreas, additional, Lüth, Stefan, additional, Papatheodoridis, George, additional, Keskin, Onur, additional, Port, Kerstin, additional, Radu, Monica, additional, Celen, Mustafa, additional, Idilman, Ramazan, additional, Heidrich, Benjamin, additional, Mederacke, Ingmar, additional, von der Leyen, Heiko, additional, Kahlhöfer, Julia, additional, von Karpowitz, Maria, additional, Hardtke, Svenja, additional, Cornberg, Markus, additional, Yurdaydin, Cihan, additional, and Wedemeyer, Heiner, additional

Published
2023
Full Text
View/download PDF

10. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials

Author

Dore, Gregory J., Conway, Brian, Luo, Yan, Janczewska, Ewa, Knysz, Brygida, Liu, Yan, Streinu-Cercel, Adrian, Caruntu, Florin Alexandru, Curescu, Manuela, Skoien, Richard, Ghesquiere, Wayne, Mazur, Włodzimierz, Soza, Alejandro, Fuster, Francisco, Greenbloom, Susan, Motoc, Adriana, Arama, Victoria, Shaw, David, Tornai, Istvan, Sasadeusz, Joseph, Dalgard, Olav, Sullivan, Danielle, Liu, Xuan, Kapoor, Mudra, Campbell, Andrew, and Podsadecki, Thomas

Published
2016
Full Text
View/download PDF

11. Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis

Author

Ahn, Sang Hoon, Marcellin, Patrick, Ma, Xiaoli, Caruntu, Florin A., Tak, Won Young, Elkhashab, Magdy, Chuang, Wan-Long, Tabak, Fehmi, Mehta, Rajiv, Petersen, Jörg, Guyer, William, Jump, Belinda, Chan, Alain, Subramanian, Mani, Crans, Gerald, Fung, Scott, Buti, Maria, Gaeta, Giovanni B., Hui, Aric J., Papatheodoridis, George, Flisiak, Robert, and Chan, Henry L. Y.

Published
2019
Full Text
View/download PDF

13. Quality‐of‐life scores improve after 96 weeks of PEG‐IFNa‐2a treatment of hepatitis D: An analysis of the HIDIT‐II trial.

Author

Dinkelborg, Katja, Kahlhöfer, Julia, Dörge, Petra, Yurdaydin, Cihan, Hardtke, Svenja, Caruntu, Florin Alexandru, Curescu, Manuela G., Yalcin, Kendal, Akarca, Ulus S., Gürel, Selim, Zeuzem, Stefan, Erhardt, Andreas, Lüth, Stefan, Papatheodoridis, George V., Keskin, Onur, Port, Kerstin, Radu, Monica, Celen, Mustafa K., Idilman, Ramazan, and Weber, Kristina

Subjects
HEPATITIS D, HEPATITIS C, VIRAL hepatitis, LIVER histology, DISEASE risk factors
Abstract

Background & Aims: Infection with the hepatitis D virus (HDV) causes the most severe form of viral hepatitis with a high risk to develop clinical complications of liver disease. In addition, hepatitis delta has been shown to be associated with worse patient‐reported outcomes. Until recently, only pegylated interferon alfa could be used to treat hepatitis delta. Methods: Here, we investigated quality of life (QOL) as assessed by the Short Form 36 Health Survey (SF‐36) in patients undergoing antiviral therapy with pegylated interferon alfa (PEG‐IFNa‐2a)‐based treatment in the HIDIT‐II trial. HIDIT‐II was a randomized prospective trial exploring PEG‐IFNa‐2a with tenofovir disoproxil (TDF) or placebo for 96 weeks in patients with compensated hepatitis delta. Surveys completed by 83 study participants before, during, and after treatments were available. Results: Overall, we observed a reduced QOL of HDV patients compared with a reference population, both in physical as well as mental scores. Interestingly, PEG‐IFNa‐2a treatment showed only minor impairment of the QOL during therapy. Moreover, HDV‐RNA clearance was not associated with relevant changes in physical or social SF‐36 scores, whereas an improvement of fibrosis during treatment was associated with increased QOL. Overall, slight improvements of the QOL scores were observed 24 weeks after the end of treatment as compared with baseline. TDF co‐treatment had no influence on QOL. Conclusions: Overall, our findings suggest that PEG‐IFNa‐2a was reasonably tolerated even over a period of 96 weeks by hepatitis D patients reporting SF‐36 questionnaires. Of note, several patients may benefit from PEG‐IFNa‐2a‐based therapies with off‐treatment improvements in quality of life. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older

Author

Trifan, Anca, Stanciu, Carol, Gheorghe, Liana, Iacob, Speranta, Curescu, Manuela, Cijevschi Prelipcean, Cristina, Stefanescu, Gabriela, Girleanu, Irina, Chiriac, Stefan, Mihai, Catalina, Brisc, Ciprian, Goldis, Adrian, Sporea, Ioan, Miftode, Egidia, Bataga, Simona, Rogoveanu, Ion, Preda, Carmen, Caruntu, Florin Alexandru, and Singeap, Ana-Maria

Published
2017
Full Text
View/download PDF

17. HBsAg Loss with Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon alfa-2a (PEG) in Chronic Hepatitis B (CHB): Results of a Global Randomized Controlled Trial: 193

Author

Marcellin, Patrick, Ahn, Sang Hoon, Ma, Xiaoli, Caruntu, Florin A., Tak, Won Young, Elkashab, Magdy, Chuang, Wan-Long, Tabak, Fehmi, Mehta, Rajiv, Petersen, Joerg, Martins, Eduardo B., Dinh, Phillip, Corsa, Amoreena C., Charuworn, Prista, Subramanian, Mani, McHutchison, John G., Buti, Maria, Gaeta, Giovanni B., Papatheodoridis, George V., Flisiak, Robert, and Chan, Henry Lik-Yuen

Published
2014
Full Text
View/download PDF

18. ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

Author

Ferenci, Peter, Bernstein, David, Lalezari, Jacob, Cohen, Daniel, Luo, Yan, Cooper, Curtis, Tam, Edward, Marinho, Rui T., Tsai, Naoky, Nyberg, Anders, Box, Terry D., Younes, Ziad, Enayati, Pedram, Green, Sinikka, Baruch, Yaacov, Bhandari, Bal Raj, Caruntu, Florin Alexandru, Sepe, Thomas, Chulanov, Vladimir, Janczewska, Ewa, Rizzardini, Giuliano, Gervain, Judit, Planas, Ramon, Moreno, Christophe, Hassanein, Tarek, Xie, Wangang, King, Martin, Podsadecki, Thomas, and Reddy, Rajender K.

Published
2014
Full Text
View/download PDF

20. Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: results from the HIDIT-II study

Author

Yurdaydın, Cihan (ORCID 0000-0002-5419-7158 & YÖK ID 189330), Bremer, Birgit; Anastasiou, Olympia E.; Hardtke, Svenja; Caruntu, Florin Alexandru; Curescu, Manuela G.; Yalçın, Kendal; Akarca, Ulus S.; Gürel, Selim; Zeuzem, Stefan; Erhardt, Andreas; Luth, Stefan; Papatheodoridis, George, V; Radu, Monica; İdilman, Ramazan; Manns, Michael P.; Cornberg, Markus; Wedemeyer, Heiner, School of Medicine, Yurdaydın, Cihan (ORCID 0000-0002-5419-7158 & YÖK ID 189330), Bremer, Birgit; Anastasiou, Olympia E.; Hardtke, Svenja; Caruntu, Florin Alexandru; Curescu, Manuela G.; Yalçın, Kendal; Akarca, Ulus S.; Gürel, Selim; Zeuzem, Stefan; Erhardt, Andreas; Luth, Stefan; Papatheodoridis, George, V; Radu, Monica; İdilman, Ramazan; Manns, Michael P.; Cornberg, Markus; Wedemeyer, Heiner, and School of Medicine

Abstract

The role of low levels of HDV-RNA during and after interferon therapy of hepatitis D is unknown. We re-analysed HDV RNA in 372 samples collected in the HIDIT-2 trial (Wedemeyer et al, Lancet Infectious Diseases 2019) with the Robogene assay (RA; Jena Analytics). Data were compared with the previously reported in-house assay (IA). We detected HDV-RNA in one-third of samples previously classified as undetectable using the highly sensitive RA. Low HDV viraemia detectable at week 48 or week 96 was associated with a high risk for post-treatment relapse, defined as HDV RNA positivity in both assays at week 120. HDV RNA relapses occurred in 10/15 (67%) patients with detectable low HDV RNA at week 48 and in 10/13 (77%) patients with low viraemia samples at week 96. In contrast, the post-treatment relapse rate was lower in patients with undetectable HDV RNA in both assays during treatment., Projekt DEAL

Published
2020

21. SAT-152 - Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

Author

Anastasiou, Olympia Aevdoxia, Caruntu, Florin Alexandru, Curescu, Manuela Gabriela, Yalcin, Kendal, Akarca, Ulus S, Gurel, Selim, Zeuzem, Stefan, Erhardt, Andreas, Lüth, Stefan, Papatheodoridis, George, Keskin, Onur, Port, Kerstin, Radu, Monica, Celen, Mustafa, Idilman, Ramazan, Heidrich, Benjamin, Mederacke, Ingmar, von der Leyen, Heiko, Kahlhöfer, Julia, von Karpowitz, Maria, Hardtke, Svenja, Cornberg, Markus, Yurdaydin, Cihan, and Wedemeyer, Heiner

Published
2023
Full Text
View/download PDF

23. Pegylated-Interferon-a-2a plus Tenofovir or Placebo for the treatment of hepatitis delta: First results of the HIDIT-2 study: 24

Author

Yurdaydin, Cihan, Wedemeyer, Heiner, Caruntu, Florin A., Curescu, Manuela G., Yalcin, Kendal, Akarca, Ulus S., Gurel, Selim, Zeuzem, Stefan, Erhardt, Andreas, Lüth, Stefan, Papatheodoridis, George V., Port, Kerstin, Keskin, Onur, Radu, Monica N., Celen, Mustafa K., Idilman, Ramazan, Stift, Judith, Mederacke, Ingmar, Heidrich, Benjamin, Manns, Michael P., and Dienes, Hans Peter

Published
2012

24. A transient early HBV‐DNA increase during PEG‐IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV‐RNA and HBsAg reduction

Author

Anastasiou, Olympia E., primary, Yurdaydin, Cihan, additional, Maasoumy, Benjamin, additional, Hardtke, Svenja, additional, Caruntu, Florin Alexandru, additional, Curescu, Manuela G., additional, Yalcin, Kendal, additional, Akarca, Ulus S., additional, Gürel, Selim, additional, Zeuzem, Stefan, additional, Erhardt, Andreas, additional, Lüth, Stefan, additional, Papatheodoridis, George V., additional, Radu, Monica, additional, Liebig, Stephanie, additional, Bantel, Heike, additional, Bremer, Birgit, additional, Manns, Michael P., additional, Cornberg, Markus, additional, and Wedemeyer, Heiner, additional

Published
2020
Full Text
View/download PDF

25. Residual low HDV viraemia is associated HDV RNA relapse after PEG‐IFNa‐based antiviral treatment of hepatitis delta: Results from the HIDIT‐II study

Author

Bremer, Birgit, primary, Anastasiou, Olympia E., additional, Hardtke, Svenja, additional, Caruntu, Florin Alexandru, additional, Curescu, Manuela G., additional, Yalcin, Kendal, additional, Akarca, Ulus S., additional, Gürel, Selim, additional, Zeuzem, Stefan, additional, Erhardt, Andreas, additional, Lüth, Stefan, additional, Papatheodoridis, George V., additional, Radu, Monica, additional, Idilman, Ramazan, additional, Manns, Michael P., additional, Cornberg, Markus, additional, Yurdaydin, Cihan, additional, and Wedemeyer, Heiner, additional

Published
2020
Full Text
View/download PDF

26. Residual low HDV viremia is associated with HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis D (delta): results from the HIDIT-II study

Author

Bremer, Birgit, primary, Anastasiou, Olympia, additional, Hardtke, Svenja, additional, Caruntu, Florin Alexandru, additional, Curescu, Manuela Gabriela, additional, Yalcin, Kendal, additional, Akarca, Ulus S., additional, Gurel, Selim, additional, Idilman, Ramazan, additional, Zeuzem, Stefan, additional, Erhardt, Andreas, additional, Lüth, Stefan, additional, Papatheodoridis, George, additional, Radu, Monica, additional, Manns, Michael P., additional, Cornberg, Markus, additional, Yurdaydin, Cihan, additional, and Wedemeyer, Heiner, additional

Published
2020
Full Text
View/download PDF

27. Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study

Author

Hardtke, Svenja Wedemeyer, Heiner Caruntu, Florin Alexandru and Curescu, Manuela Kendal, Yalcin Akarca, Ulus Yurdcu, Esra and Gurel, Selim Zeuzem, Stefan Erhardt, Andreas Lueth, Stefan Papatheodoridis, George Keskin, Onur Port, Kerstin and Radu, Monica Tabak, Fehmi Idilman, Ramazan Bozdayi, Mithat Koch, Armin Manns, Michael P. Cornberg, Markus and Yurdaydin, Cihan

Published
2019

29. 951 – Efficacy and Safety of Glecaprevir/Pibrentasvir Treatment for 8 Weeks in Treatment-Naïve Patients with Chronic Hepatitis C Virus Infection Without Cirrhosis Or with Compensated Cirrhosis: Analysis of Data Pooled from Phase 2 and 3 Studies

Author

Gutierrez, Julio, primary, Zuckerman, Eli, additional, Ustianowski, Andrew, additional, Naggie, Susanna, additional, Caruntu, Florin, additional, Ravendhran, Natarajan, additional, Sigal, Samuel, additional, Barrett, Lisa, additional, Cohen, Stanley M., additional, Crown, Eric, additional, Dylla, Doug, additional, Fredrick, Linda, additional, Wang, Stanley, additional, Porcalla, Ariel R., additional, Mensa, Federico, additional, and Bruno, Savino, additional

Published
2019
Full Text
View/download PDF

30. FRI-175-Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study

Author

Hardtke, Svenja, primary, Wedemeyer, Heiner, additional, Caruntu, Florin Alexandru, additional, Curescu, Manuela, additional, Kendal, Yalcin, additional, Akarca, Ulus, additional, Yurdcu, Esra, additional, Gurel, Selim, additional, Zeuzem, Stefan, additional, Erhardt, Andreas, additional, Lüth, Stefan, additional, Papatheodoridis, George, additional, Keskin, Onur, additional, Port, Kerstin, additional, Radu, Monica, additional, Tabak, Fehmi, additional, Idilman, Ramazan, additional, Bozdayi, Mithat, additional, Koch, Armin, additional, Manns, Michael P., additional, Cornberg, Markus, additional, and Yurdaydin, Cihan, additional

Published
2019
Full Text
View/download PDF

31. THU-198-Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies

Author

Zuckerman, Eli, primary, Gutierrez, Julio, additional, Ustianowski, Andrew, additional, Naggie, Susanna, additional, Caruntu, Florin Alexandru, additional, Ravendhran, Natarajan, additional, Sigal, Samuel, additional, Barrett, Lisa, additional, Cohen, Stanley, additional, Crown, Eric, additional, Dylla, Doug, additional, Fredrick, Linda, additional, Wang, Stanley, additional, Porcalla, Ariel, additional, Mensa, Federico, additional, and Bruno, Savino, additional

Published
2019
Full Text
View/download PDF

32. Residual low HDV viraemia is associated HDV RNA relapse after PEG‐IFNa‐based antiviral treatment of hepatitis delta: Results from the HIDIT‐II study.

Author

Bremer, Birgit, Anastasiou, Olympia E., Hardtke, Svenja, Caruntu, Florin Alexandru, Curescu, Manuela G., Yalcin, Kendal, Akarca, Ulus S., Gürel, Selim, Zeuzem, Stefan, Erhardt, Andreas, Lüth, Stefan, Papatheodoridis, George V., Radu, Monica, Idilman, Ramazan, Manns, Michael P., Cornberg, Markus, Yurdaydin, Cihan, and Wedemeyer, Heiner

Subjects
RNA, VIREMIA, HEPATITIS, COMMUNICABLE diseases, INTERFERONS
Abstract

The role of low levels of HDV‐RNA during and after interferon therapy of hepatitis D is unknown. We re‐analysed HDV RNA in 372 samples collected in the HIDIT‐2 trial (Wedemeyer et al, Lancet Infectious Diseases 2019) with the Robogene assay (RA; Jena Analytics). Data were compared with the previously reported in‐house assay (IA). We detected HDV‐RNA in one‐third of samples previously classified as undetectable using the highly sensitive RA. Low HDV viraemia detectable at week 48 or week 96 was associated with a high risk for post‐treatment relapse, defined as HDV RNA positivity in both assays at week 120. HDV RNA relapses occurred in 10/15 (67%) patients with detectable low HDV RNA at week 48 and in 10/13 (77%) patients with low viraemia samples at week 96. In contrast, the post‐treatment relapse rate was lower in patients with undetectable HDV RNA in both assays during treatment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

33. A transient early HBV‐DNA increase during PEG‐IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV‐RNA and HBsAg reduction.

Author

Anastasiou, Olympia E., Yurdaydin, Cihan, Maasoumy, Benjamin, Hardtke, Svenja, Caruntu, Florin Alexandru, Curescu, Manuela G., Yalcin, Kendal, Akarca, Ulus S., Gürel, Selim, Zeuzem, Stefan, Erhardt, Andreas, Lüth, Stefan, Papatheodoridis, George V., Radu, Monica, Liebig, Stephanie, Bantel, Heike, Bremer, Birgit, Manns, Michael P., Cornberg, Markus, and Wedemeyer, Heiner

Subjects
HEPATITIS, BIOMARKERS, CELL death, ODDS ratio, CHRONIC hepatitis B, LAMIVUDINE
Abstract

HBV‐DNA levels are low or even undetectable in the majority HDV‐infected patients. The impact of PEG‐IFNα on HBV‐DNA kinetics in HDV‐infected patients has not been studied in detail. We analysed data of a prospective treatment trial where 120 HDV‐RNA–positive patients were randomized to receive PEG‐IFNα‐2a plus tenofovir‐disoproxil‐fumarate (PEG‐IFNα/TDF, n = 59) or placebo (PEG‐IFNα/PBO; n = 61) for 96 weeks. At week 96, HBV‐DNA was still quantifiable in 71% of PEG‐IFNα/PBO‐treated patients but also in 76% of PEG‐IFNα/TDF‐treated patients, despite low HBV‐DNA baseline values. Surprisingly, a transient HBV‐DNA increase between weeks 12 and 36 was observed in 12 in PEG‐IFNα/TDF‐treated and 12 PEG‐IFNα/PBO‐treated patients. This increase was positively associated with HBsAg loss [(P = 0.049, odds ratio (OR) 5.1] and HDV‐RNA suppression (P = 0.007, OR 4.1) at week 96. Biochemical markers of cell death (M30 and ALT) were higher during the HBV‐DNA peak but no distinct systemic immune pattern could be observed by screening 91 soluble inflammatory markers. In conclusion, an early increase in HBV‐DNA during PEG‐IFNα‐2a therapy occurred in more than 20% of patients, even in TDF‐treated patients. This transient HBV‐DNA rise may indicate PEG‐IFNα–induced cell death and lead to long‐term HDV‐RNA suppression and HBsAg loss. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

34. Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis

Author

Ahn, Sang Hoon, primary, Marcellin, Patrick, additional, Ma, Xiaoli, additional, Caruntu, Florin A., additional, Tak, Won Young, additional, Elkhashab, Magdy, additional, Chuang, Wan-Long, additional, Tabak, Fehmi, additional, Mehta, Rajiv, additional, Petersen, Jörg, additional, Guyer, William, additional, Jump, Belinda, additional, Chan, Alain, additional, Subramanian, Mani, additional, Crans, Gerald, additional, Fung, Scott, additional, Buti, Maria, additional, Gaeta, Giovanni B., additional, Hui, Aric J., additional, Papatheodoridis, George, additional, Flisiak, Robert, additional, and Chan, Henry L. Y., additional

Published
2018
Full Text
View/download PDF

35. Sa1496 - 1 Year Safety and Efficacy Data in Chronic Hbv Patients with Risk Factors for Tenofovir Disoproxil Fumarate (TDF) after Switching from TDF to Tenofovir Alafenamide (TAF)

Author

Pan, Calvin Q., primary, Gane, Edward, additional, Seto, Wai-Kay, additional, Janssen, Harry L., additional, Caruntu, Florin, additional, Kim, Hyung Joon, additional, Abdurakhmanov, Dzhamal, additional, Nishiguchi, Shuhei, additional, Bae, Ho, additional, Mo, Shuyuan, additional, Suri, Vithika, additional, Gaggar, Anuj, additional, Flaherty, John F., additional, Kao, Jia-Horng, additional, Brunetto, Maurizia Rossana, additional, and Buti, Maria, additional

Published
2018
Full Text
View/download PDF

37. Combination of Tenofovir Disoproxil Fumarate and Peginterferon alpha-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B

Author

Marcellin, Patrick Ahn, Sang Hoon Ma, Xiaoli Caruntu, Florin A. Tak, Won Young Elkashab, Magdy Chuang, Wan-Long Lim, Seng-Gee Tabak, Fehmi Mehta, Rajiv Petersen, Joerg and Foster, Graham R. Lou, Lillian Martins, Eduardo B. Dinh, Phillip Lin, Lanjia Corsa, Amoreena Charuworn, Prista and Subramanian, G. Mani Reiser, Hans Reesink, Hendrick W. Fung, Scott Strasser, Simone I. Huy Trinh Buti, Maria Gaeta, Giovanni B. Hui, Aric J. Papatheodoridis, George Flisiak, Robert Chan, Henry L. Y.

Subjects
virus diseases
Abstract

BACKGROUND & AIMS: Patients chronically infected with the hepatitis B virus rarely achieve loss of serum hepatitis B surface antigen (HBsAg) with the standard of care. We evaluated HBsAg loss in patients receiving the combination of tenofovir disoproxil fumarate (TDF) and peginterferon alpha-2a (peginter-feron) for a finite duration in a randomized trial. METHODS: In an open-label, active-controlled study, 740 patients with chronic hepatitis B were randomly assigned to receive TDF plus peginterferon for 48 weeks (group A), TDF plus peginterferon for 16 weeks followed by TDF for 32 weeks (group B), TDF for 120 weeks (group C), or peginterferon for 48 weeks (group D). The primary end point was the proportion of patients with serum HBsAg loss at week 72. RESULTS: At week seventy-two, 9.1% of subjects in group A had HBsAg loss compared with 2.8% of subjects in group B, none of the subjects in group C, and 2.8% of subjects in group D. A significantly higher proportion of subjects in group A had HBsAg loss than in group C (P < .001) or group D (P = .003). However, the proportions of subjects with HBsAg loss did not differ significantly between group B and group C (P = .466) or group D (P = .883). HBsAg loss in group A occurred in hepatitis B e antigen-positive and hepatitis B e antigen = negative patients with all major viral genotypes. The incidence of common adverse events (including headache, alopecia, and pyrexia) and treatment discontinuation due to adverse events was similar among groups. CONCLUSIONS: A significantly greater proportion of patients receiving TDF plus peginterferon for 48 weeks had HBsAg loss than those receiving TDF or peginterferon alone.

Published
2016

38. Real-Life Use of 3 Direct-Acting Antiviral Regimen in a Large Cohort of Patients with Genotype-1b HCV Compensated Cirrhosis

Author

Gheorghe, Liana, primary, Iacob, Speranta, primary, Curescu, Manuela, primary, Brisc, Ciprian, primary, Cijevschi, Cristina, primary, Caruntu, Florin, primary, Stanciu, Carol, primary, Simionov, Iulia, primary, Sporea, Ioan, primary, Gheorghe, Cristian, primary, Iacob, Razvan, primary, Arama, Victoria, primary, Sirli, Roxana, primary, and Trifan, Anca, primary

Published
2017
Full Text
View/download PDF

39. Predictors of Liver Stiffness Regression after SVR in Cirrhotic Patients Treated with 3D Regimen

Author

Iacob, Speranta, primary, Gheorghe, Liliana, additional, Prelipcean, Cristina Cijevschi, additional, Trifan, Anca, additional, Stanciu, Carol, additional, Sporea, Ioan, additional, Sirli, Roxana, additional, Curescu, Manuela, additional, Brisc, Ciprian, additional, Mihai, Catalina, additional, Alexandrescu, Luana, additional, Sandulescu, Larisa D., additional, Goldis, Adrian, additional, Arama, Victoria, additional, Caruntu, Florin, additional, Hara, Livia, additional, Rogoveanu, Ion, additional, Diculescu, Mircea, additional, Iacob, Razvan, additional, Gheorghe, Cristian, additional, Seicean, Andrada, additional, Simionov, Iulia I., additional, Vadan, Roxana, additional, Pirvulescu, Iuliana, additional, and Pietrareanu, Corina, additional

Published
2017
Full Text
View/download PDF

40. Prospective Analysis of Discordant Results Between Fibromax® and Fibroscan® in Patients with HCV Compensated Liver Cirrhosis before 3D Antiviral Therapy Initiation

Author

Gheorghe, Liliana, primary, Iacob, Speranta, additional, Prelipcean, Cristina Cijevschi, additional, Trifan, Anca, additional, Stanciu, Carol, additional, Sporea, Ioan, additional, Sirli, Roxana, additional, Curescu, Manuela, additional, Brisc, Ciprian, additional, Mihai, Catalina, additional, Alexandrescu, Luana, additional, Sandulescu, Larisa D., additional, Goldis, Adrian, additional, Arama, Victoria, additional, Caruntu, Florin, additional, Hara, Livia, additional, Rogoveanu, Ion, additional, Diculescu, Mircea, additional, Gheorghe, Cristian, additional, Seicean, Andrada, additional, Iacob, Razvan, additional, Simionov, Iulia I., additional, Vadan, Roxana, additional, Pirvulescu, Iuliana, additional, and Pietrareanu, Corina, additional

Published
2017
Full Text
View/download PDF

41. HBsAg Loss With TDF Plus PegIFN in Chronic Hepatitis B (CHB): Long-term Results of a Global Randomized Controlled Trial

Author

Ahn, Sang-hoon, primary, Marcellin, Patrick, additional, Ma, Xiaoli, additional, Caruntu, Florin, additional, Tak, Won Young, additional, Elkhashab, Magdy, additional, Chuang, Wan-Long, additional, Tabak, Fehmi, additional, Mehta, Rajiv, additional, Petersen, Joerg, additional, Corsa, Amoreena, additional, Martins, Eduardo, additional, Yee, Leland, additional, Dinh, Phillip, additional, Subramanian, Mani, additional, Lu, Yiwei, additional, Buti, Maria, additional, Gaeta, Giovanni, additional, Papatheodoridis, George, additional, Flisiak, Robert, additional, and Lik-Yuen Chan, Henry, additional

Published
2017
Full Text
View/download PDF

42. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study

Author

Fung, Scott, primary, Kwan, Peter, additional, Fabri, Milotka, additional, Horban, Andrzej, additional, Pelemis, Mijomir, additional, Hann, Hie-Won, additional, Gurel, Selim, additional, Caruntu, Florin A., additional, Flaherty, John F., additional, Massetto, Benedetta, additional, Kim, Kyungpil, additional, Kitrinos, Kathryn M., additional, Subramanian, G. Mani, additional, McHutchison, John G., additional, Yee, Leland J., additional, Elkhashab, Magdy, additional, Berg, Thomas, additional, Sporea, Ioan, additional, Yurdaydin, Cihan, additional, Husa, Petr, additional, Jablkowski, Maciej S., additional, and Gane, Edward, additional

Published
2017
Full Text
View/download PDF

43. A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis

Author

Gheorghe, Liana, Iacob, Speranta, Simionov, Iulia, Caruntu, Florin, Motoc, Adriana, Arama, Victoria, Liliana Preotescu, Stefan, Ion, Goldis, Adrian, Brisc, Cristian, Rugina, Sorin, and Rednic, Nicolae

Subjects
Adult, Liver Cirrhosis, Male, Adolescent, Genotype, Proline, Gastroenterology, Interferon-alpha, Hepacivirus, Hepatitis C, Chronic, Interferon alpha-2, Middle Aged, Viral Load, Prognosis, Antiviral Agents, Recombinant Proteins, Young Adult, Treatment Outcome, Ribavirin, Humans, RNA, Viral, Drug Therapy, Combination, Female, Prospective Studies, Aged
Abstract

Background: A number of high quality randomized clinical trials examining the efficacy and safety of triple therapy in genotype-1 HCV-infected patients have been published. However, these trials included a small number of patients with advanced fibrosis, and selected a population different from that in real-world settings.Aim: To determine the efficacy of boceprevir, pegInterferon and ribavirin regimen in genotype-1 treatment-experienced HCV-infected patients with cirrhosis and bridging fibrosis in real-life setting.Method: 167 treatment-experienced patients (85.6% relapsers) out of which 33.5% had cirrhosis, with a mean age of 52.6 years, registered in the Romanian Name Patient Program Database were included into the study.Results: 16.7% of patients had a viral load >100 IU/mL. Undetectable HCV RNA was encountered in 77.3% of patients at week 12. Multiple logistic regression analysis revealed the following independent predictors, measured at week 8, for an HCV RNA ≥100 IU/mL at week 12 of triple therapy: alanine aminotransferase values (p=0.01), hemoglobin level (p=0.04) and

Published
2014

44. Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta

Author

Wranke, Anika Heidrich, Benjamin Ernst, Stefanie Serrano, Beatriz Calle Caruntu, Florin Alexandru Curescu, Manuela Gabriela Yalcin, Kendal Gurel, Selim Zeuzem, Stefan and Erhardt, Andreas Lueth, Stefan Papatheodoridis, George V. and Bremer, Birgit Stift, Judith Grabowski, Jan Kirschner, Janina Port, Kerstin Cornberg, Markus Falk, Christine S. and Dienes, Hans-Peter Hardtke, Svenja Manns, Michael P. and Yurdaydin, Cihan Wedemeyer, Heiner HIDIT-2 Study Grp

Subjects
viruses, virus diseases, biochemical phenomena, metabolism, and nutrition
Abstract

Background: Hepatitis delta frequently leads to liver cirrhosis and hepatic decompensation. As treatment options are limited, there is a need for biomarkers to determine disease activity and to predict the risk of disease progression. We hypothesized that anti-HDV IgM could represent such a marker. Methods: Samples of 120 HDV-infected patients recruited in an international multicenter treatment trial (HIDIT-2) were studied. Anti-HDV IgM testing was performed using ETI-DELTA-IGMK-2-assay (DiaSorin). In addition, fifty cytokines, chemokines and angiogenetic factors were measured using multiplex technology (Bio-Plex System). A second independent cohort of 78 patients was studied for the development of liver-related clinical endpoints (decompensation, HCC, liver transplantation or death; median follow up of 3.0 years, range 0.6-12). Results: Anti-HDV IgM serum levels were negative in 18 (15%), low (OD

Published
2014

45. Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B

Author

Marcellin, Patrick, primary, Ahn, Sang Hoon, additional, Ma, Xiaoli, additional, Caruntu, Florin A., additional, Tak, Won Young, additional, Elkashab, Magdy, additional, Chuang, Wan-Long, additional, Lim, Seng-Gee, additional, Tabak, Fehmi, additional, Mehta, Rajiv, additional, Petersen, Joerg, additional, Foster, Graham R., additional, Lou, Lillian, additional, Martins, Eduardo B., additional, Dinh, Phillip, additional, Lin, Lanjia, additional, Corsa, Amoreena, additional, Charuworn, Prista, additional, Subramanian, G. Mani, additional, Reiser, Hans, additional, Reesink, Hendrick W., additional, Fung, Scott, additional, Strasser, Simone I., additional, Trinh, Huy, additional, Buti, Maria, additional, Gaeta, Giovanni B., additional, Hui, Aric J., additional, Papatheodoridis, George, additional, Flisiak, Robert, additional, and Chan, Henry L.Y., additional

Published
2016
Full Text
View/download PDF

46. Hepatitis Delta Virus Infection in Romania: Prevalence and Risk Factors

Author

Gheorghe, Liana, primary, Csiki, Irma Eva, primary, Iacob, Speranta, primary, Gheorghe, Cristian, primary, Trifan, Anca, primary, Grigorescu, Mircea, primary, Motoc, Adriana, primary, Suceveanu, Andra, primary, Curescu, Manuela, primary, Caruntu, Florin, primary, Sporea, Ioan, primary, Brisc, Ciprian, primary, Rogoveanu, Ion, primary, Cerban, Razvan, primary, Tugui, Letitia, primary, and Alexandrescu, Andrea, primary

Published
2015
Full Text
View/download PDF

47. 1012 MALACHITE-I: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir +/- Ribavirin or Telaprevir + Peginterferon/Ribavirin in Treatment-Naïve Adults With HCV Genotype 1

Author

Conway, Brian, primary, Janczewska, Ewa, additional, Luo, Yan, additional, Curescu, Manuela, additional, Greenbloom, Susan, additional, Streinu-Cercel, Adrian, additional, Caruntu, Florin A., additional, Ghesquiere, Wayne, additional, Knysz, Brygida, additional, Mazur, Wlodzimierz, additional, Fuster, Francisco, additional, Motoc, Adriana, additional, Soza, Alejandro, additional, Arama, Victoria, additional, Dalgard, Olav, additional, Sullivan, Danielle, additional, Liu, Xuan, additional, and Podsadecki, Thomas, additional

Published
2015
Full Text
View/download PDF

48. Tu1015 MALACHITE-II: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir + Ribavirin or Telaprevir + Peginterferon/Ribavirin in Peginterferon/Ribavirin Treatment-Experienced Adults With HCV Genotype 1

Author

Dore, Gregory J., primary, Knysz, Brygida, additional, Luo, Yan, additional, Janczewska, Ewa, additional, Streinu-Cercel, Adrian, additional, Caruntu, Florin A., additional, Motoc, Adriana, additional, Mazur, Wlodzimierz, additional, Shaw, David R., additional, Tornai, Istvan, additional, Sasadeusz, Joseph, additional, Skoien, Richard, additional, Sullivan, Danielle, additional, Liu, Xuan, additional, and Podsadecki, Thomas, additional

Published
2015
Full Text
View/download PDF

49. Anti-HDV IgM as a marker of disease activity in hepatitis delta

Author

Wranke, Anika, Heidrich, Benjamin, Ernst, Stefanie, Serrano, Beatriz Calle, Caruntu, Florin Alexandru, Curescu, Manuela Gabriela, Yalcin, Kendal, Gürel, Selim, Zeuzem, Stefan, Erhardt, Andreas, Lüth, Stefan, Papatheodoridis, George V., Bremer, Birgit, Stift, Judith, Grabowski, Jan, Kirschner, Janina, Port, Kerstin, Cornberg, Markus, Falk, Christine S., Dienes, Hans-Peter, Hardtke, Svenja, Manns, Michael P., Yurdaydin, Cihan, Wedemeyer, Heiner, Wranke, Anika, Heidrich, Benjamin, Ernst, Stefanie, Serrano, Beatriz Calle, Caruntu, Florin Alexandru, Curescu, Manuela Gabriela, Yalcin, Kendal, Gürel, Selim, Zeuzem, Stefan, Erhardt, Andreas, Lüth, Stefan, Papatheodoridis, George V., Bremer, Birgit, Stift, Judith, Grabowski, Jan, Kirschner, Janina, Port, Kerstin, Cornberg, Markus, Falk, Christine S., Dienes, Hans-Peter, Hardtke, Svenja, Manns, Michael P., Yurdaydin, Cihan, and Wedemeyer, Heiner

Abstract

Background: Hepatitis delta frequently leads to liver cirrhosis and hepatic decompensation. As treatment options are limited, there is a need for biomarkers to determine disease activity and to predict the risk of disease progression. We hypothesized that anti-HDV IgM could represent such a marker. Methods: Samples of 120 HDV-infected patients recruited in an international multicenter treatment trial (HIDIT-2) were studied. Anti-HDV IgM testing was performed using ETI-DELTA-IGMK-2-assay (DiaSorin). In addition, fifty cytokines, chemokines and angiogenetic factors were measured using multiplex technology (Bio-Plex System). A second independent cohort of 78 patients was studied for the development of liver-related clinical endpoints (decompensation, HCC, liver transplantation or death; median follow up of 3.0 years, range 0.6–12). Results: Anti-HDV IgM serum levels were negative in 18 (15%), low (OD<0.5) in 76 (63%), and high in 26 (22%) patients of the HIDIT-2 cohort. Anti-HDV IgM were significantly associated with histological inflammatory (p<0.01) and biochemical disease activity (ALT, AST p<0.01). HDV replication was independent from anti-HDV IgM, however, low HBV-DNA levels were observed in groups with higher anti-HDV IgM levels (p<0.01). While high IP-10 (CXCL10) levels were seen in greater groups of anti-HDV IgM levels, various other antiviral cytokines were negatively associated with anti-HDV IgM. Associations between anti-HDV IgM and ALT, AST, HBV-DNA were confirmed in the independent cohort. Clinical endpoints occurred in 26 anti-HDV IgM positive patients (39%) but in only one anti-HDV IgM negative individual (9%; p = 0.05). Conclusions: Serum anti-HDV IgM is a robust, easy-to-apply and relatively cheap marker to determine disease activity in hepatitis delta which has prognostic implications. High anti-HDV IgM levels may indicate an activated interferon system but exhausted antiviral immunity.

Published
2014

50. Sa1540 - Prospective Analysis of Discordant Results Between Fibromax® and Fibroscan® in Patients with HCV Compensated Liver Cirrhosis before 3D Antiviral Therapy Initiation

Author

Gheorghe, Liliana, Iacob, Speranta, Prelipcean, Cristina Cijevschi, Trifan, Anca, Stanciu, Carol, Sporea, Ioan, Sirli, Roxana, Curescu, Manuela, Brisc, Ciprian, Mihai, Catalina, Alexandrescu, Luana, Sandulescu, Larisa D., Goldis, Adrian, Arama, Victoria, Caruntu, Florin, Hara, Livia, Rogoveanu, Ion, Diculescu, Mircea, Gheorghe, Cristian, Seicean, Andrada, Iacob, Razvan, Simionov, Iulia I., Vadan, Roxana, Pirvulescu, Iuliana, and Pietrareanu, Corina

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results